Itovebi (inavolisib) — Highmark
Endocrine-resistant, locally advanced or metastatic breast cancer
Initial criteria
- age ≥ 18 years
- Diagnosis of endocrine-resistant, locally advanced or metastatic breast cancer (ICD-10: C50)
- Disease is HR-positive, HER2-negative
- Disease is PIK3CA-mutated as detected by an FDA-approved test
- Used in combination with palbociclib (Ibrance) AND fulvestrant
- Experienced recurrence on or after completing adjuvant endocrine therapy
Reauthorization criteria
- Prescriber attests the member is tolerating therapy AND has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months